Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy
P Fisel, E Schaeffeler, M Schwab - Clinical and translational …, 2018 - Wiley Online Library
The solute carrier (SLC) SLC16 gene family comprises 14 members and encodes for
monocarboxylate transporters (MCTs), which mediate the absorption and distribution of …
monocarboxylate transporters (MCTs), which mediate the absorption and distribution of …
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
H Bruckmueller, I Cascorbi - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
[HTML][HTML] Genetic polymorphisms associated with rheumatoid arthritis development and antirheumatic therapy response
DS Mikhaylenko, MV Nemtsova, IV Bure… - International journal of …, 2020 - mdpi.com
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy worldwide. Possible
manifestations of RA can be represented by a wide variability of symptoms, clinical forms …
manifestations of RA can be represented by a wide variability of symptoms, clinical forms …
Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors
KX Zhang, CK Ip, SK Chung, KK Lei, YQ Zhang… - Current opinion in …, 2020 - Elsevier
Highlights•The correlation between p53 mutations, P-gp overexpression, and gain-of-
function in p53 mutants might contribute to drug-resistant RA.•Targeting the ABC …
function in p53 mutants might contribute to drug-resistant RA.•Targeting the ABC …
[HTML][HTML] Polymorphisms and pharmacogenomics for the clinical efficacy of methotrexate in patients with rheumatoid arthritis: a systematic review and meta-analysis
Q Qiu, J Huang, X Shu, H Fan, Y Zhou, C Xiao - Scientific Reports, 2017 - nature.com
Methotrexate (MTX) is widely used and considered a first-line disease modifying anti-
rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Many of the relevant …
rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Many of the relevant …
[HTML][HTML] Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta …
Q Qiu, J Huang, Y Lin, X Shu, H Fan, Z Tu, Y Zhou… - Medicine, 2017 - journals.lww.com
Background: Methotrexate (MTX) is widely used and considered a first-line disease
modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA) …
modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA) …
Prediction of clinically relevant drug‐induced liver injury from structure using machine learning
F Hammann, V Schöning… - Journal of Applied …, 2019 - Wiley Online Library
Drug‐induced liver injury (DILI) is the most common cause of acute liver failure and often
responsible for drug withdrawals from the market. Clinical manifestations vary, and toxicity …
responsible for drug withdrawals from the market. Clinical manifestations vary, and toxicity …
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis
B Jekic, N Maksimovic, T Damnjanovic - Pharmacogenomics, 2019 - Future Medicine
For many decades, methotrexate (MXT) has remained the drug of choice in the treatment of
rheumatoid arthritis (RA). Unfortunately, a considerable number of patients do not achieve …
rheumatoid arthritis (RA). Unfortunately, a considerable number of patients do not achieve …
Predicting methotrexate resistance in rheumatoid arthritis patients
MB Yu, A Firek, WHR Langridge - Inflammopharmacology, 2018 - Springer
Rheumatoid arthritis (RA) is an incurable, systemic autoimmune disease that decreases
quality of life and can lead to severe disability. While there are many medications available …
quality of life and can lead to severe disability. While there are many medications available …
Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome
Aim: Evaluate the potential of selected SNPs as predictors of methotrexate (MTX)
therapeutic outcome. Patients & methods: In total, 35 SNPs in 14 genes involved in MTX …
therapeutic outcome. Patients & methods: In total, 35 SNPs in 14 genes involved in MTX …